Small Molecule Targeted Cancer Therapy Market to Receive Overwhelming Hike in Revenues by 2025

New market research study provides an analysis and evaluation of the current and prospective profitability, liquidity and financial stability of ****** Small Molecule Targeted Cancer Therapy Industry.

Small molecule targeted cancer therapies are designed to block the growth of cancerous cells in the body. Usually, rapidly dividing cancer cells’ cell division is inhibited by conventional cytotoxic medications and chemotherapies. But, the mechanism of action of small molecule targeted therapies have an added advantage of destroying cancerous cells with high precision and relatively fewer side effects. Treatment of various cancers such as breast cancer, melanoma, multiple myeloma, prostate cancer lymphoma, and other cancers can be done via small molecule targeted cancer therapy.

One of the essential drivers of this market is the high adoption rates of this therapy. Glaxo Smith Kline sponsored a program where International Society of Nurse in Cancer Care’s nurses led a Small Molecule Chemotherapy Patient Education Program that was aimed at adhering self-care capacity of patients going through small molecule therapy. Thus, such supportive initiatives enhance the adoption rate of this therapy thereby fueling the market growth.

A report by International Agency for Research on Cancer (IARC) suggests that a total of 13 million new cancer cases are diagnosed worldwide whereas the World Cancer Report provides the rate of new cancer cases, which is expected to increase by 50% to 15 million by 2020. Thus increasing incidence of cancer is projected to escalate the market growth. Additionally, patent expiration of essential drugs is expected to act as an opportunity for manufacturers of target release drugs. For instance, patent of Glivec drug manufactured by Novartis is due to expire, thereby opening new avenues for small molecule targeted cancer therapy market.

Obtain Report Details with Technological Advancement at

Among various treatment methods, small molecules targeted therapy is preferred owing to convenience in administration and lesser costs. For instance, treatment via small molecules can be developed to target any cell location, unlike monoclonal antibodies treatment methods. MAbs are also inefficient in delivering drugs to the brain tissues as the blood–brain barrier prohibits entry of molecules larger in weight, thus small molecules have an added advantage as they can be delivered intra-tumorally. Moreover, FDA claims that the half-life of mAbs like cetuximab (3.1-7.8 days) is much longer than certain small-molecule operatives like gefitinib (48 hours). Furthermore, small molecules are capable of penetrating the interstices of a tumor and target intra-cellular signaling protein. Their identification and purity can be ensured by various scientific methods making them easy to reproduce and they can also be administered orally unlike antibodies that are administered intravenously. It is estimated that further research over small molecules might prove to be an alternative to the antibodies in cancer immunotherapy.

Small molecule targeted cancer therapy market is classified as small molecules, small molecule drug conjugates, and monoclonal antibodies. The small molecules segment is further classified into small molecule tyrosine kinase inhibitor (imatinib), small molecule cyclin-dependent kinase inhibitor (seliciclib), and small molecule proteasome inhibitor (bortezomib). Based on monoclonal antibodies, the market can be further segmented into humanized monoclonal antibody (with a circulatory system target), fully human antibody (with an immune system target), chimeric monoclonal antibody (with a tumor target), and humanized monoclonal antibody (with a circulatory system target). Geographically, North America, Europe, and Asia Pacific are expected to experience dominance of this market.

Get Sample PDF with Technological Trends at

The North American region is anticipated to dominate the market owing to the increasing prevalence of cancer. In a report, the National Institute of Health estimates that in U.S. alone, the medical expenditure for cancer is expected to cross $150 billion by 2020. Thus, growing incidence of cancer and lesser side effects of small molecule targeted therapy are expected to propel the market growth in North America further over the forecast period.

Key players of the small molecule targeted cancer therapy market are Boehringer Ingelheim GmbH, Abbott Laboratories, Cytokinetics Inc., Bayer HealthCare AG, OncoGenex Pharmaceuticals Inc., Hospira Inc., and GlaxoSmithKline PLC.

About Us:

Xpodence Research is a U.S. based Market Research Company and offers the most extensive collection of progressive surveying syndicated and customized research reports of various categories for private and public industries across the globe.

We offer the comprehensive market research solution for all the industries by performing the in-depth study of industry trends, verticals globally. We believe in building an eternal bond with our customers through providing them inclusive research study both customized and syndicated based on their specific requirements.

The organizations in every industry such as Technology, Pharmaceuticals, Consumable Goods, Food & Beverage and others demands a market-based solutions for various significant decisions based on productivity and output globally. Our services are tailored specifically to our clients by proposing them the potential outcome, based on our in-depth analysis and insights for exploring the growth strategies through providing the best possible decision for quality production.

Contact Us:

244 , Madison Avenue
New York City, NY – 10016
United States
Toll Free: +1- 844-445-2861

Phone: +1- 347-983-9688


Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.